Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

embership interest in the joint venture to Spectrum, CTI will receive $6 million, with the remainder of the $18 million to be paid within 90 days following such closing. The closing of the sale option transaction is contingent upon the satisfaction of certain closing conditions, including the delivery of a legal opinion from counsel to CTI, as specified in the operating agreement for the Zevalin joint venture. CTI believes that it will be in a position to promptly satisfy all of the closing conditions.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, lowgrade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be use
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... September 18, 2014 Texas Governor ... Sharp, Texas A&M Health Science Center CEO Brett ... of Health and Human Services (HHS), State of ... national pandemic influenza vaccine manufacturing facility in Bryan, ... anchor for the Texas A&M Biocorridor – a ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... LI-COR Biosciences has released a,new Technical ... the Odyssey Infrared,Imaging System. The E-PAGE 48- ... a high-throughput SDS-PAGE,method for processing protein samples. ... System, up to 96 different proteins samples can ...
... 19 PharmAthene, Inc.,(NYSE Alternext US: PIP), a ... threats, announced today that,it has signed an agreement ... in Israel. , ... combat the risk of,terrorist attacks with biological or ...
... Jazz Pharmaceuticals,Inc. (Nasdaq: JAZZ ) announced that it ... Capital Markets 5th Annual Healthcare,Conference due to the proximity of ... pivotal clinical trial of JZP-6 (sodium oxybate) for,the treatment of ... anticipates that it will release the preliminary top-line data,within the ...
Cached Biology Technology:Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 3PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 4
(Date:9/18/2014)... camouflage: you don,t just blend in, the background shows ... as you might think. Kathryn Feller, from the University ... life stages of many marine species are transparent. However, ... creatures cannot make transparent. Feller explains that the animals ... unit with an opaque pigment to prevent light leaking ...
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
(Date:9/17/2014)... scientists were instrumental in the creation of the Santa ... classify the fire threat potential of the powerful, hot, ... into an inferno. The index was introduced Sept. 17 ... and San Diego Gas and Electric. , The index ... that will be used to help fire agencies and ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... of the brain, which scavenge pathogens and damaged neurons, are ... research by Duke neuroscientists. Earlier studies by Staci Bilbo, ... laboratory rats experiencing an infection at an early age have ... their learning and memory. In a study published ...
... Lake City Physicians preparing to deliver a baby look ... whether or not to perform a C- section. But a ... shows that those heart rate patterns may not be a ... lead to unnecessary interventions and higher costs. "We,re trying ...
... a class of theoretical concepts for manipulating the climate ... caused by greenhouse gasses. But its potential effectiveness and ... could help narrow these uncertainties. A team composed of ... and Harvard,s David Keith used modeling to determine the ...
Cached Biology News:Source found for immune system effects on learning, memory 2Source found for immune system effects on learning, memory 3New study finds fetal heart rate not a good indicator of a baby's health 2New study finds fetal heart rate not a good indicator of a baby's health 3Testing geoengineering 2
ANTI DIPHTH TOX A SU...
... Kit (E-22013) provides,researchers with a sensitive ... in solution. This fluorescence-based assay can ... (Figure 1). The assay,measures lysozyme activity ... labeled to such a degree that ...
... m7G(5')ppp(5')G (Cap Analog) is used for the ... in vitro transcription reactions. Substitution of cap ... GTP in an in vitro transcription reaction ... structure into a large fraction of the ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. It can incubate up to ...
Biology Products: